126 related articles for article (PubMed ID: 36116416)
1. Role of genetic testing in hepatic, pancreatic, and biliary cancers.
Hewitt DB; Aziz H; Brown ZJ; Pawlik TM
Surg Oncol; 2022 Sep; 44():101844. PubMed ID: 36116416
[TBL] [Abstract][Full Text] [Related]
2. Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies.
Wan S; Zhao E; Weissinger D; Krantz BA; Werba G; Freeman D; Khanna LG; Siolas D; Oberstein PE; Chattopadhyay PK; Simeone DM; Welling TH
Front Immunol; 2023; 14():1067352. PubMed ID: 36798126
[TBL] [Abstract][Full Text] [Related]
3. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules.
Gandou C; Harada K; Sato Y; Igarashi S; Sasaki M; Ikeda H; Nakanuma Y
Hum Pathol; 2013 May; 44(5):811-21. PubMed ID: 23134772
[TBL] [Abstract][Full Text] [Related]
4. Hilar cholangiocarcinoma is pathologically similar to pancreatic duct adenocarcinoma: suggestions of similar background and development.
Nakanuma Y; Sato Y
J Hepatobiliary Pancreat Sci; 2014 Jul; 21(7):441-7. PubMed ID: 24446421
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
6. Trends and disparities in the utilization of systemic chemotherapy in patients with metastatic hepato-pancreato-biliary cancers.
Elshami M; Ahmed FA; Kakish H; Hue JJ; Hoehn RS; Rothermel LD; Bajor D; Mohamed A; Selfridge JE; Ammori JB; Hardacre JM; Winter JM; Ocuin LM
HPB (Oxford); 2023 Feb; 25(2):239-251. PubMed ID: 36411233
[TBL] [Abstract][Full Text] [Related]
7. The cellular origins of cancer with particular reference to the gastrointestinal tract.
Alison MR
Int J Exp Pathol; 2020 Oct; 101(5):132-151. PubMed ID: 32794627
[TBL] [Abstract][Full Text] [Related]
8. Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas.
Zaccari P; Cardinale V; Severi C; Pedica F; Carpino G; Gaudio E; Doglioni C; Petrone MC; Alvaro D; Arcidiacono PG; Capurso G
World J Gastroenterol; 2019 Aug; 25(31):4343-4359. PubMed ID: 31496617
[TBL] [Abstract][Full Text] [Related]
9. [Systemic treatment of liver and biliary tumors].
Malek NP; Greten T; Kubicka S
Internist (Berl); 2007 Jan; 48(1):46-9. PubMed ID: 17177032
[TBL] [Abstract][Full Text] [Related]
10. Pathologic classification of cholangiocarcinoma: New concepts.
Nakanuma Y; Kakuda Y
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):277-93. PubMed ID: 25966428
[TBL] [Abstract][Full Text] [Related]
11. Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct.
Singhi AD; Wood LD; Parks E; Torbenson MS; Felsenstein M; Hruban RH; Nikiforova MN; Wald AI; Kaya C; Nikiforov YE; Favazza L; He J; McGrath K; Fasanella KE; Brand RE; Lennon AM; Furlan A; Dasyam AK; Zureikat AH; Zeh HJ; Lee K; Bartlett DL; Slivka A
Gastroenterology; 2020 Feb; 158(3):573-582.e2. PubMed ID: 31678302
[TBL] [Abstract][Full Text] [Related]
12. Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma.
Mosbeh A; Halfawy K; Abdel-Mageed WS; Sweed D; Rahman MHA
Cancer Genet; 2018 Aug; 224-225():21-28. PubMed ID: 29778232
[TBL] [Abstract][Full Text] [Related]
13. Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data.
Bagante F; Spolverato G; Ruzzenente A; Luchini C; Tsilimigras DI; Campagnaro T; Conci S; Corbo V; Scarpa A; Guglielmi A; Pawlik TM
Eur J Cancer; 2021 May; 148():348-358. PubMed ID: 33774439
[TBL] [Abstract][Full Text] [Related]
14. FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience.
Hrudka J; Prouzová Z; Mydlíková K; Jedličková K; Holešta M; Whitley A; Havlůj L
Pathol Oncol Res; 2021; 27():1609756. PubMed ID: 34257615
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
Chung V
Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
[TBL] [Abstract][Full Text] [Related]
16. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
[TBL] [Abstract][Full Text] [Related]
17. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
[No Abstract] [Full Text] [Related]
18. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
Ruff SM; Shannon AH; Pawlik TM
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
[TBL] [Abstract][Full Text] [Related]
19. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
Cercek A; D'Angelica M; Power D; Capanu M; Gewirtz A; Patel D; Allen P; Fong Y; DeMatteo RP; Jarnagin WR; Kemeny NE
Ann Surg Oncol; 2014 Feb; 21(2):479-86. PubMed ID: 24154839
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
Schweitzer N; Vogel A
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
